
## Marjolijn Duijm-de Carpentier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9612403/publications.pdf

Version: 2024-02-01



Marjolijn Duijm-de

#	Article	IF	CITATIONS
1	Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications, 2020, 11, 3083.	12.8	173
2	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). Journal of the National Cancer Institute, 2018, 110, 40-48.	6.3	138
3	Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. Clinical Cancer Research, 2021, 27, 311-319.	7.0	58
4	Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial. Breast Cancer Research and Treatment, 2021, 185, 741-758.	2.5	27
5	Tumorâ€stroma ratio is associated with <scp>Millerâ€Payne</scp> score and pathological response to neoadjuvant chemotherapy in <scp>HER2</scp> â€negative early breast cancer. International Journal of Cancer, 2021, 149, 1181-1188.	5.1	24
6	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. Journal of Clinical Oncology, 2020, 38, 3273-3281.	1.6	20
7	Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. European Journal of Cancer, 2018, 95, 59-67.	2.8	7
8	Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer. Breast Cancer Research and Treatment, 2018, 168, 413-420.	2.5	5
9	Predictive performance of breast cancer index (BCI) and clinical treatment score post-5 years (CTS5) in the IDEAL study Journal of Clinical Oncology, 2022, 40, 545-545.	1.6	1